- Report
- April 2025
- 307 Pages
Global
From €3438EUR$3,825USD£3,015GBP
€4045EUR$4,500USD£3,547GBP
- Report
- August 2025
- 189 Pages
Global
From €3186EUR$3,545USD£2,794GBP
€3540EUR$3,939USD£3,105GBP
- Report
- July 2025
- 250 Pages
Global
From €4036EUR$4,490USD£3,539GBP
- Report
- February 2025
- 200 Pages
Global
From €4036EUR$4,490USD£3,539GBP
- Report
- September 2025
- 250 Pages
Global
From €4036EUR$4,490USD£3,539GBP
- Report
- April 2025
- 200 Pages
Global
From €4036EUR$4,490USD£3,539GBP
- Report
- November 2025
- 50 Pages
Global
From €2382EUR$2,650USD£2,089GBP
Strontium-89 is a radiopharmaceutical used in Nuclear Medicine and Radiopharmacology. It is a radioactive isotope of strontium, and is used to treat bone pain caused by metastatic prostate cancer. It is administered intravenously, and is taken up by the bone, where it emits beta radiation to reduce pain. Strontium-89 is also used to diagnose bone metastases, and to monitor the effectiveness of treatments.
The Strontium-89 market is composed of companies that produce and distribute the radiopharmaceutical. These companies include Eckert & Ziegler, Jubilant DraxImage, IBA Molecular, and Nordion. Show Less Read more
